



FOR IMMEDIATE RELEASE

Media Contact: Ashley Hart
602.615.2949
ashleyhartpr@cox.net

The Anne Rita Monahan Foundation Partners with TGen to Further Ovarian Cancer Research

ARM Donates \$10,000 to TGen's Ovarian Cancer Research Project

PHOENIX—February 27, 2008 — The Anne Rita Monahan Foundation, ARM Yourself Against Ovarian Cancer (ARM), has recently partnered with the Translational Genomics Research Institute (TGen) to help advance ovarian cancer research. The ARM Foundation, which launched in September of last year, announces its first donation of \$10,000 to the Arizona-based research organization. The funding will go to an ovarian cancer-specific clinical trial project that is currently underway at TGen.

“It is a pleasure to work with an organization like the Anne Rita Monahan Foundation that supports the research necessary to make strides against ovarian cancer,” said Dr. Heather Cunliffe, head of the Breast and Ovarian Cancer Research Lab at TGen. “We look forward to a strong, ongoing partnership that will help us both reach our goals.”

The ARM Foundation plans to raise an additional \$90,000 this year that will be donated to this project, which is designed to develop a robust test that will predict whether a patient’s ovarian cancer will be sensitive or resistant to chemotherapy. This will involve use of state-of-the-art high-resolution technologies to measure the biology and behavior of ovarian cancer. The same molecular information from this study will also be utilized toward development of a non-invasive screening test to detect disease onset before symptoms of ovarian cancer occur.

“The ARM Foundation is thrilled to be aligning with TGen because it does so much valuable research specific to ovarian cancer,” said Anne Monahan, founder and president of the ARM Foundation. “This is only the beginning of a long-term relationship that will benefit women everywhere as we work together to eradicate this terrible disease.”

-more-

ARM Partners with TGen

Page 2

Monahan is a stage-4 ovarian cancer fighter who launched her Foundation to help other women avoid the devastating effects ovarian cancer can cause. To help reach its goal, **the ARM Foundation will hold its first fundraiser of the year on Thursday, April 3rd, from 6 to 8 p.m. at Duck and Decanter, a restaurant located at 1651 East Camelback Road in Phoenix.** The event will be open to the public and will feature a wine tasting, food and prize raffles.

The Foundation strives to raise awareness among women of the signs and symptoms of ovarian cancer, which include: bloating, pelvic or abdominal pain, difficulty eating or feeling full quickly and an urgency or frequency to urinate. Any woman experiencing these symptoms for more than two weeks should alert a gynecological specialist. For more information on the ARM Foundation or the upcoming fundraiser, please visit www.anneritamohan.org or call 602-264-5539.

About the Anne Rita Monahan Foundation

The Anne Rita Monahan Foundation is a nonprofit, 501(c)(3) organization, which was established on Sept. 1, 2007. The Foundation's aim is to create awareness of the signs and symptoms of ovarian cancer in order to encourage early detection and decrease cases of misdiagnosis. In addition, the Foundation raises funds to aid in finding a reliable screening test for this disease. With the mission to eradicate ovarian cancer, the Foundation continues to promote awareness and early detection. For more information on the ARM Foundation, or for information about volunteering or contributing to this important cause, please visit www.anneritamohan.org or call 602-264-5539.

About TGen

The Translational Genomics Research Institute (TGen) is a non-profit 501(c)(3) organization dedicated to the performance of groundbreaking research with life changing results. Research at TGen is focused on developing earlier diagnostics and smarter treatments for diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process. TGen's vision is of a world where an understanding of genomic variation can be rapidly translated to the diagnosis and treatment of disease in a manner tailored to individual patients.

###